Samsung Group’s biologic drug manufacturing arm announced fresh details on its plans for a November listing, the same day its subsidiary said it had sought European approval for a near-replica of top-selling cancer drug Herceptin.
http://on.wsj.com/2dncv9K
No comments:
Post a Comment